Covid 19 Research using Clinical Trials (Home Page)
Report for D009471: Neuromyelitis Optica NIH
(Synonyms: Neuromy, Neuromyelitis Optica)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug293 | Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) Wiki | 1.00 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Cohort Study Evaluating the Epidemiological Characteristics of Coronavirus Infection (SARS-CoV-2) in Patients With MS or NMO
The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19. The objective of this study is to provide scientific information regarding the possible risk factors in these patients, as a large part of them receive immunomodulatory or immunosuppressive treatments. The main objective of this study is thus to determine the epidemiological (eg, age, form of disease, disability) and pharmacological (related to immunomodulatory or immunosuppressive treatments) factors favoring the occurrence of a severe form of Covid-19 in MS and NMO patients.
NCT04355611 Multiple Sclerosis NMO Spectrum Disorder COVID-19 Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) MeSH:Multiple Sclerosis Neuromyelitis Optica
Primary Outcomes
Description: The main outcome measure is a clinical severity score on a 7-point severity scale at Nadir (in medicine, the most severe point in the progression of symptoms of a pathology). Nadir scale from 1 : Not hospitalized, no limitation of activities to 7 :Death
Measure: Clinical severity Time: 6 monthsSecondary Outcomes
Description: EDSS is the Expanded Disability Severity Scale, a measure of neurological disability in patients with MS or NMO. EDSS Scale from 0: normal neurological examination to 10: MS-related Death
Measure: EDSS (Expanded Disability Status Scale) Time: 6 months